Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Cell-specific targeting of lentiviral vectors mediated by fusion proteins derived from Sindbis virus, vesicular stomatitis virus, or avian sarcoma/leukosis virus.

Zhang XY, Kutner RH, Bialkowska A, Marino MP, Klimstra WB, Reiser J.

Retrovirology. 2010 Jan 25;7:3. doi: 10.1186/1742-4690-7-3.

2.

Cell type-specific targeting with sindbis pseudotyped lentiviral vectors displaying anti-CCR5 single-chain antibodies.

Aires da Silva F, Costa MJ, Corte-Real S, Goncalves J.

Hum Gene Ther. 2005 Feb;16(2):223-34.

PMID:
15761262
3.

Engineered lentiviral vectors pseudotyped with a CD4 receptor and a fusogenic protein can target cells expressing HIV-1 envelope proteins.

Lee CL, Dang J, Joo KI, Wang P.

Virus Res. 2011 Sep;160(1-2):340-50. doi: 10.1016/j.virusres.2011.07.010. Epub 2011 Jul 23.

4.
5.

Redirecting lentiviral vectors pseudotyped with Sindbis virus-derived envelope proteins to DC-SIGN by modification of N-linked glycans of envelope proteins.

Morizono K, Ku A, Xie Y, Harui A, Kung SK, Roth MD, Lee B, Chen IS.

J Virol. 2010 Jul;84(14):6923-34. doi: 10.1128/JVI.00435-10. Epub 2010 May 19.

6.

RD114 envelope proteins provide an effective and versatile approach to pseudotype lentiviral vectors.

Bell AJ Jr, Fegen D, Ward M, Bank A.

Exp Biol Med (Maywood). 2010 Oct;235(10):1269-76. doi: 10.1258/ebm.2010.010053. Epub 2010 Sep 27.

PMID:
20876083
7.

Packaging HIV- or FIV-based lentivector expression constructs and transduction of VSV-G pseudotyped viral particles.

Mendenhall A, Lesnik J, Mukherjee C, Antes T, Sengupta R.

J Vis Exp. 2012 Apr 8;(62):e3171. doi: 10.3791/3171.

8.

Targeted gene delivery to CD117-expressing cells in vivo with lentiviral vectors co-displaying stem cell factor and a fusogenic molecule.

Froelich S, Ziegler L, Stroup K, Wang P.

Biotechnol Bioeng. 2009 Sep 1;104(1):206-15. doi: 10.1002/bit.22378.

9.

Measles virus glycoprotein-based lentiviral targeting vectors that avoid neutralizing antibodies.

Kneissl S, Abel T, Rasbach A, Brynza J, Schneider-Schaulies J, Buchholz CJ.

PLoS One. 2012;7(10):e46667. doi: 10.1371/journal.pone.0046667. Epub 2012 Oct 10.

11.

Cocal-pseudotyped lentiviral vectors resist inactivation by human serum and efficiently transduce primate hematopoietic repopulating cells.

Trobridge GD, Wu RA, Hansen M, Ironside C, Watts KL, Olsen P, Beard BC, Kiem HP.

Mol Ther. 2010 Apr;18(4):725-33. doi: 10.1038/mt.2009.282. Epub 2009 Dec 8.

12.

Efficient transduction of equine adipose-derived mesenchymal stem cells by VSV-G pseudotyped lentiviral vectors.

Petersen GF, Hilbert B, Trope G, Kalle W, Strappe P.

Res Vet Sci. 2014 Dec;97(3):616-22. doi: 10.1016/j.rvsc.2014.09.004. Epub 2014 Oct 6.

PMID:
25443656
13.

Characterization of retroviral and lentiviral vectors pseudotyped with xenotropic murine leukemia virus-related virus envelope glycoprotein.

Sakuma T, De Ravin SS, Tonne JM, Thatava T, Ohmine S, Takeuchi Y, Malech HL, Ikeda Y.

Hum Gene Ther. 2010 Dec;21(12):1665-73. doi: 10.1089/hum.2010.063. Epub 2010 Sep 17.

14.

Targeting lentiviral vector to specific cell types through surface displayed single chain antibody and fusogenic molecule.

Lei Y, Joo KI, Zarzar J, Wong C, Wang P.

Virol J. 2010 Feb 11;7:35. doi: 10.1186/1743-422X-7-35.

16.

Targeted cell entry of lentiviral vectors.

Funke S, Maisner A, Mühlebach MD, Koehl U, Grez M, Cattaneo R, Cichutek K, Buchholz CJ.

Mol Ther. 2008 Aug;16(8):1427-36. doi: 10.1038/mt.2008.128. Epub 2008 Jun 24.

17.

Altering the tropism of lentiviral vectors through pseudotyping.

Cronin J, Zhang XY, Reiser J.

Curr Gene Ther. 2005 Aug;5(4):387-98. Review. Erratum in: Curr Gene Ther. 2005 Oct;5(5):531.

18.
20.

Characterization of a third generation lentiviral vector pseudotyped with Nipah virus envelope proteins for endothelial cell transduction.

Witting SR, Vallanda P, Gamble AL.

Gene Ther. 2013 Oct;20(10):997-1005. doi: 10.1038/gt.2013.23. Epub 2013 May 23.

Supplemental Content

Support Center